Alterity Therapeutics Limited
corporate_fare Company Profile
Alterity Therapeutics Limited (NASDAQ:ATHE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for ATHE at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Alterity Therapeutics Presents Strong Phase 2 ATH434 Data, Outlines Clear Phase 3 Path for MSA Treatment
- Alterity Therapeutics Publishes Study Validating MRI Biomarker for MSA, Supporting ATH434 Development
- Alterity Therapeutics to Present Positive Phase 2 MSA Data and Phase 3 Plans at Medical Conferences
- Alterity Therapeutics Reports Strong Cash Position, 9.4 Quarters Runway, and Advances ATH434 Program
- Formalizes 1-for-50 Reverse Stock Split, Details Timetable for Share Consolidation
Financial Snapshot
Insider Transactions
ATHE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.